It is now clear that treatment of certain solid and liquid tumors with targeted monoclonal antibodies (mAb) can improve clinical outcome for many patients. It is also clear that in many instances this mAb therapy requires participation from the innate immune system. Nonetheless, tumors themselves exploit innate immune tolerance so as to weaken effective participation by the latter, thereby contributing to the fact that mAb therapy is still not curable today. In this competing renewal application we hypothesize that a better understanding of how the tumor exploits innate immune effector cell tolerance will lead to novel therapeutic options that largely reverse this process and enhance mAb therapy of cancer. To achieve this Project 1 (PI: J Byrd) plans to disrupt human B cell signaling in chronic lymphocytic leukemia with two novel compounds, examine innate immune effector cell function, and move to the clinic combining these agents with mAb B cell therapy;Project 2 (PI: S Tridandapani) will explore negative regulators of human monocytes / macrophage Fc? receptor signaling, as well as immune activators that reverse such negative regulators in order to improve antibody dependent cellular cytotoxicity (ADCC) of both liquid and solid tumors. Project 3 (PI: M Caligiuri) examines the mechanisms by which human natural killer (NK) cells acquire Fc?Rlll, and characterizes negative regulators of NK ADCC. Two clinical trials will then inhibit this negative signaling in order to enhance NK ADCC against lymphoma and NK cytotoxicity against multiple myeloma;Project 4 (PI: W Carson) examines the mechanism by which myeloid derived suppressor cells suppress innate effector cell ADCC, and explores different mechanisms to deplete these suppressor cells in order to enhance ADCC in the laboratory and in the solid tumor clinic. These four projects are served by the unique resources provided by Core A (Administration), Core B (Biostatistics) and Core C (Mouse Modeling and Animal Development). For the past 4.5 years, investigators within this P01 have published 51 collaborative manuscripts and have accrued 815 patients to clinical trials emanating from this P01. The next 5 years of work will result in improved clinical outcome of cancer patients undergoing with mAb therapy.

Public Health Relevance

Monoclonal antibody (mAb) therapy of cancer has improved clinical outcome for patients with both liquid and solid tumors, but by-in-large it is not curative. This program projec grant will elucidate how tumors weaken the immune system, thereby preventing more effective mAb therapy of cancer. Several clinical trials will be undertaken that will reverse this suppression in order to see if mAb therapy of cancer can be strengthened.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA095426-13
Application #
8730541
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Merritt, William D
Project Start
2002-02-01
Project End
2017-08-31
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
13
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Ohio State University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
Columbus
State
OH
Country
United States
Zip Code
43210
Freud, Aharon G; Mundy-Bosse, Bethany L; Yu, Jianhua et al. (2017) The Broad Spectrum of Human Natural Killer Cell Diversity. Immunity 47:820-833
Duggan, Megan C; Stiff, Andrew R; Bainazar, Maryam et al. (2017) Identification of NRAS isoform 2 overexpression as a mechanism facilitating BRAF inhibitor resistance in malignant melanoma. Proc Natl Acad Sci U S A 114:9629-9634
Long, Meixiao; Beckwith, Kyle; Do, Priscilla et al. (2017) Ibrutinib treatment improves T cell number and function in CLL patients. J Clin Invest 127:3052-3064
Victor, Aaron R; Nalin, Ansel P; Dong, Wenjuan et al. (2017) IL-18 Drives ILC3 Proliferation and Promotes IL-22 Production via NF-?B. J Immunol 199:2333-2342
Wesolowski, Robert; Duggan, Megan C; Stiff, Andrew et al. (2017) Circulating myeloid-derived suppressor cells increase in patients undergoing neo-adjuvant chemotherapy for breast cancer. Cancer Immunol Immunother 66:1437-1447
Markowitz, Joseph; Wang, Jiang; Vangundy, Zach et al. (2017) Nitric oxide mediated inhibition of antigen presentation from DCs to CD4+ T cells in cancer and measurement of STAT1 nitration. Sci Rep 7:15424
Campbell, Amanda R; Duggan, Megan C; Suarez-Kelly, Lorena P et al. (2017) MICA-Expressing Monocytes Enhance Natural Killer Cell Fc Receptor-Mediated Antitumor Functions. Cancer Immunol Res 5:778-789
Suarez-Kelly, Lorena P; Campbell, Amanda R; Rampersaud, Isaac V et al. (2017) Fluorescent nanodiamonds engage innate immune effector cells: A potential vehicle for targeted anti-tumor immunotherapy. Nanomedicine 13:909-920
Dai, Hong-Sheng; Griffin, Nathaniel; Bolyard, Chelsea et al. (2017) The Fc Domain of Immunoglobulin Is Sufficient to Bridge NK Cells with Virally Infected Cells. Immunity 47:159-170.e10
McMichael, Elizabeth L; Jaime-Ramirez, Alena Cristina; Guenterberg, Kristan D et al. (2017) IL-21 Enhances Natural Killer Cell Response to Cetuximab-Coated Pancreatic Tumor Cells. Clin Cancer Res 23:489-502

Showing the most recent 10 out of 283 publications